Rawpixel / Shutterstock.com
Philip Johnson, Johnson & Johnson’s senior vice president of intellectual property and policy, told the BIO International Convention yesterday that uncertainty around patent eligibility of inventions is a “silent killer of innovation”.
Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on email@example.com.
BIO 2015, Johnson & Johnson, Sequenom, patent eligibility, diagnostic patents, BIO International Convention 2015, David Kappos